Abstract
One-third of the worlds population is infected with Mycobacterium (M.) tuberculosis. Tuberculosis continues to be the most common infectious cause of death and still has a serious impact, medically, socially and financially. Multidrug-resistant tuberculosis (MDR-TB), caused by tubercle bacilli that are resistant to at least isoniazid and rifampin, is among the most worrisome elements of the pandemic of antibiotic resistance because TB patients for whom treatment has failed have a high risk of death. Drugs used to treat tuberculosis are classified into first-line and second-line agents. First-line essential anti-tuberculosis agents are the most effective, and are a necessary component of any short-course therapeutic regimen. The drugs in this category are isoniazid, rifampin, ethambutol, pyrazinamide and streptomycin. Second-line anti-tuberculosis drugs are clinically much less effective than first-line agents and elicit severe reactions much more frequently. These drugs include para-aminosalicylic acid (PAS), ethionamide, cycloserine, amikacin and capreomycin. New drugs, which are yet to be assigned to the above categories, include rifapentine, levofloxacin, gatifloxacin and moxifloxacin. Recently there has been much development in the molecular pharmacology of anti-tuberculosis drugs. This review summarizes information for isoniazid, rifampicin, ethambutol, pyrazinamide, and fluoroquinolones, and describes their resistance mechanisms.
Keywords: Isoniazid, Mycobacterium tuberculosis, Rifamycins, embCAB gene, Pyrazinoic acid
Mini-Reviews in Medicinal Chemistry
Title: Overview of Anti-Tuberculosis (TB) Drugs and Their Resistance Mechanisms
Volume: 7 Issue: 11
Author(s): Ruiru Shi, Nobunori Itagaki and Isamu Sugawara
Affiliation:
Keywords: Isoniazid, Mycobacterium tuberculosis, Rifamycins, embCAB gene, Pyrazinoic acid
Abstract: One-third of the worlds population is infected with Mycobacterium (M.) tuberculosis. Tuberculosis continues to be the most common infectious cause of death and still has a serious impact, medically, socially and financially. Multidrug-resistant tuberculosis (MDR-TB), caused by tubercle bacilli that are resistant to at least isoniazid and rifampin, is among the most worrisome elements of the pandemic of antibiotic resistance because TB patients for whom treatment has failed have a high risk of death. Drugs used to treat tuberculosis are classified into first-line and second-line agents. First-line essential anti-tuberculosis agents are the most effective, and are a necessary component of any short-course therapeutic regimen. The drugs in this category are isoniazid, rifampin, ethambutol, pyrazinamide and streptomycin. Second-line anti-tuberculosis drugs are clinically much less effective than first-line agents and elicit severe reactions much more frequently. These drugs include para-aminosalicylic acid (PAS), ethionamide, cycloserine, amikacin and capreomycin. New drugs, which are yet to be assigned to the above categories, include rifapentine, levofloxacin, gatifloxacin and moxifloxacin. Recently there has been much development in the molecular pharmacology of anti-tuberculosis drugs. This review summarizes information for isoniazid, rifampicin, ethambutol, pyrazinamide, and fluoroquinolones, and describes their resistance mechanisms.
Export Options
About this article
Cite this article as:
Shi Ruiru, Itagaki Nobunori and Sugawara Isamu, Overview of Anti-Tuberculosis (TB) Drugs and Their Resistance Mechanisms, Mini-Reviews in Medicinal Chemistry 2007; 7 (11) . https://dx.doi.org/10.2174/138955707782331740
DOI https://dx.doi.org/10.2174/138955707782331740 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bactericidal and Hemolytic Activities of Synthetic Peptides Derived from Granulysin
Protein & Peptide Letters Progress in Structure-Based Design of EGFR Inhibitors
Current Drug Targets Anti-infective Agents Produced by the Hyphomycetes Genera Trichoderma and Gliocladium
Current Medicinal Chemistry - Anti-Infective Agents Editorial (Thematic Issue: Role of Data and Methods in Chemoinformatics for Virtual Screening)
Combinatorial Chemistry & High Throughput Screening Ultra-Sensitive Electrochemical Sensor for the Determination of Pyrazinamide
Current Analytical Chemistry Structure-Activity Relationships and Mechanism of Action of Macrolides Derived from Erythromycin as Antibacterial Agents
Current Topics in Medicinal Chemistry Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews Antibiotics in the Treatment of Reactive Arthritis
Current Rheumatology Reviews Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry Preface:
Current Topics in Medicinal Chemistry Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Pulmonary Sarcoidosis Presenting with Miliary Opacities
Current Medical Imaging Anti-Tubercular and Anti-Inflammatory Activities of Azetidin-2-One Derivatives and Their Effects on the Activity of Phospholipase A2
Medicinal Chemistry Lipoplexes Formulation and Optimisation: In Vitro Transfection Studies Reveal No Correlation with In Vivo Vaccination Studies
Current Drug Delivery Centrality Measures in Biological Networks
Current Bioinformatics Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Current Pharmaceutical Design Cloning, Expression and Correlation of Rv0148 to Amikacin & Kanamycin Resistance
Current Proteomics DESIGN, <i>In silico</i> Modeling, Toxicity study and Synthesis of Novel Substituted Semicarbazide Derivatives of Pyrimidine: An Antitubercular Agent
Current Bioactive Compounds Antimycobacterial Activity: Synthesis and Biological Evaluation of Novel Substituted (3E,5E)-3,5-diarylidene-1-phenethylpiperidine-4-one Derivatives
Letters in Drug Design & Discovery